{"brief_title": "Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder", "brief_summary": "The main objective of this study is to compare the antidepressant efficacy and safety of DVS-233 SR versus placebo in adult outpatients with Major Depressive Disorder.", "condition": "Major Depressive Disorder", "intervention_type": "Drug", "intervention_name": "DVS-233 SR", "criteria": "Inclusion Criteria: - Outpatients - Men and women age 18 years of age and older - Women of childbearing potential participating in the study must have a negative serum pregnancy test result at screening and use a medically acceptable form of contraception Exclusion Criteria: - Treatment with DVS-233 SR at any time in the past - Treatment with venlafaxine (immediate release [IR] or extended release [ER]) within 90 days of study day 1 - Known hypersensitivity to venlafaxine (IR or ER) - Significant risk of suicide based on clinical judgment, including common", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00092911.xml"}